Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02473016
Other study ID # C402
Secondary ID
Status Completed
Phase Phase 2
First received May 29, 2015
Last updated November 16, 2017
Start date September 2015
Est. completion date April 2017

Study information

Verified date November 2017
Source Capnia, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A placebo-controlled, single-blind study to evaluate the safety and preliminary efficacy of nasal carbon dioxide for the symptomatic treatment of classical trigeminal neuralgia.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date April 2017
Est. primary completion date March 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male and female, 18 years of age and older.

- History of classical trigeminal neuralgia with or without persistent background facial pain, not secondary, as defined by International Classification of Headache Disorders (ICHD), third edition, beta version (ICHD-3 beta, Cephalalgia 2013).

- Diagnosis of trigeminal neuralgia (TN) for at least 60 days prior to enrollment.

- Experience pain with a score of at least 5 on a 0-10 scale during a typical TN episode as reported by subject. Note: Prior to treatment pain score must a 5 or greater on a VAS.

- History of unilateral typical TN pain predominantly in the V2 branch of the trigeminal nerve.

- Absence of a significant structural lesion (e.g., a tumor) as the cause of pain as shown in at least one neuro-imaging study.

- On stable dose of all medications, including those for the treatment of TN prevention/prophylaxis, for at least 14 days prior to baseline (including, but not limited to, verapamil, lithium, melatonin, any anticonvulsant, any systemic corticosteroid or steroid injection, occipital nerve block, other cranial or extracranial nerve block, or any neurostimulation treatment). Note: Subjects are allowed to use their usual standard of care for the acute/abortive treatment of trigeminal neuralgia attacks 60 or more minutes after the initial dose, provided it is approved by the investigator.

- Capable of completing a diary.

- Able to provide written Informed Consent.

Exclusion Criteria:

- Are unable to comply with protocol requirements.

- Have recent of alcohol or drug abuse within 2 years prior to study enrollment.

- Current major psychiatric disorder: suicidal ideation, bipolar, panic disorder, schizophrenic, or psychosis. Subjects who are documented as clinically stable and not exhibiting symptoms related to their psychiatric disorder are eligible.

- History of asthma (other than mild or intermittent).

- Have an existing serious unstable systemic disease (e.g., severe emphysema, other respiratory diseases, heart disease, etc.) that precludes participation.

- Clinically significant nasal disorder (deviated septum, presence of polyps, evidence of significant congestion, rhinitis, or other nasal abnormalities) that prevents unrestricted breathing through each nostril.

- Currently on anticoagulants or have a diagnosis of a bleeding disorder.

- Current diagnosis of fibromyalgia, temporomandibular disorders (TMD), odontogenic pain or other orofacial pain.

- Surgery for treatment of TN within 30 days prior to screening. Note: Investigator must ensure that patients who have had surgery have recovered and are not experiencing any side effects from surgery for treatment of TN

- Females who are pregnant or breast-feeding and/or plan to become pregnant or to breast-feed during study participation or within 30 days after treatment.

- Participation in a previous study with nasal CO2.

- Participation in another investigational drug study within 30 days prior to randomization.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Carbon Dioxide Drug Delivery System (CDDS)
Doses will be administered to the nostril on the side of the trigeminal episode [ipsilateral nostril].

Locations

Country Name City State
United States Medical University of South Carolina (MUSC) Charleston South Carolina
United States University of Virginia Charlottesville Virginia
United States University of California, Los Angeles (UCLA) Los Angeles California
United States Columbia University Medical Center New York New York
United States University of Pittsbugh Medical Center (UPMC) Pittsburgh Pennsylvania
United States Meridien Research Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Capnia, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain relief assessed on a visual analog scale (VAS) in a subject diary Assessed through 24 hours from initial dose
Secondary Percentage of subjects experiencing pain freedom at 5-60 minutes assessed on a visual analog scale (VAS) in a subject diary Assessed through 60 minutes post intial dose
Secondary Reduction in the number of attacks (recorded in a subject diary) Assessed through 24 hours from initial dose
Secondary Increase in duration between episodes of pain (recorded in a subject diary) Assessed through 24 hours from initial dose
Secondary Percentage of subjects with pain relief 5-60 minutes assessed on a visual analog scale (VAS) in a subject diary Assessed through 60 minutes post intial dose
Secondary Rescue medication usage (recorded in a subject diary) Assessed through 24 hours from initial dose
Secondary Subject satisfaction (recorded in a subject diary) Assessed through 24 hours from initial dose
Secondary Attack recurrence (recorded in a subject diary) Assessed through 24 hours from initial dose
Secondary Decreased trigger sensitivity (recorded in a subject diary) Assessed through 24 hours from initial dose
Secondary Reported Adverse Events (recorded in a subject diary and during follow up phone calls) Up to 7 days after inital dose
Secondary Reduction in intensity of attacks (recorded in a subject diary) Assessed through 24 hours from initial dose
See also
  Status Clinical Trial Phase
Recruiting NCT05152368 - Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Trigeminal Neuralgia and Peripheral Neuropathy Phase 1
Recruiting NCT02801630 - An Evaluation of the Effect of a Surface Acoustic Wave Patch Device on the Symptons of Trigeminal Neuralgia N/A
Recruiting NCT01364259 - A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia Phase 3
Completed NCT01364272 - Diffusion Tensor Imaging Magnetic Resonance Imaging (DTI MRI) as a Correlate to Pain Relief and Facial Numbness in Patients Following Stereotactic Radiosurgical Rhizotomy for Trigeminal Neuralgia
Completed NCT00603694 - Hippocampal Radiation Exposure and Memory N/A
Completed NCT00913107 - Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia Phase 2/Phase 3
Recruiting NCT04996199 - Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical Trial Phase 4
Completed NCT06240494 - Predictive Factors in Maxillary and Mandibular Nerve Radiofrequency Treatment for Trigeminal Neuralgia
Completed NCT05712993 - Comparative Study Between Transcoronoid and Infrazygomatic Anterior Maneuvers N/A
Completed NCT04371575 - Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients
Completed NCT03669744 - Regional Anesthesia in Refractory Trigeminal Neuralgia: 21 Cases Reported to the Limoges University Hospital
Completed NCT05032573 - Feasibility of Olive Oil for Reducing Facial Pain of Trigeminal Neuralgia N/A
Recruiting NCT05615714 - Paresthesia-free Peripheral Nerve Field Stimulation for Trigeminal Neuralgia (FreeST Trial) Phase 1/Phase 2
Recruiting NCT04054024 - Efficacy and Tolerability of Erenumab in Patients With Trigeminal Neuralgia Phase 2
Not yet recruiting NCT05451251 - Deep Brain Stimulation for Refractory Trigeminal Neuralgia With a Demyelinating Pontine Lesion N/A
Withdrawn NCT04353505 - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Phase 1
Withdrawn NCT01932255 - CSF Leak Following Microvascular Decompression: the Benefit of Routine Postoperative Lumbar Tap N/A
Completed NCT05075707 - Comparison Between Magnetic Field and Laser Therapy in Management of Trigeminal Neuralgia N/A
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Recruiting NCT03331913 - Botulinum Toxin for Trigeminal Neuralgia Phase 3